HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SMCI
Super Micro Computer, Inc.
SMCI's fundamentals are strong and it looks cheap: trading at 5.7x earnings, about a third of its usual 19x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SMCI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Weak | |
| Strong |
SMCI's revenue, profitability and balance sheet are currently strong, but its cash flow is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SMCI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.3x | $26.99 | — |
| Current | 5.7x | $26.99 | — |
| Cheap | 13x | $61.50 | +128% |
| Fair | 19x | $88.86 | +229% |
| Expensive | 26x | $125 | +363% |
Historical ranges are pointers, not guarantees.
SMCI's PE is in its cheap range at 5.7x. If earnings grow as analysts expect, today's price would be 4.3x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SMCI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Moderate | |
| Low |
SMCI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SMCI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.22 | +31% |
| Q3 2026 | $4.75 | +274% |
| Q2 2026 | $3.26 | +94% |
| Q1 2026 | $1.91 | +4.4% |
| Q4 2025 | $1.36 | -41% |
| Q3 2025 | $1.27 | -45% |
| Q2 2025 | $1.68 | -13% |
| Q1 2025 | $1.83 | +2.8% |
| Q4 2024 | $2.32 | +81% |
SMCI has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SMCI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.9B | +298% |
| Q2 2026 | $11.1B | +93% |
| Q1 2026 | $10.2B | +123% |
| Q4 2025 | $12.7B | +123% |
| Q3 2025 | $5B | -15% |
| Q2 2025 | $5.8B | +7.5% |
| Q1 2025 | $4.6B | +19% |
| Q4 2024 | $5.7B | +55% |
SMCI's revenue has grown year over year for four quarters in a row: $19.9B last quarter, up 298% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +6.7 points |
| Q2 2026 | 13% | +9.4 points |
| Q1 2026 | 6.1% | +2.9 points |
| Q4 2025 | 3.7% | -2.8 points |
| Q3 2025 | 3.6% | -5 points |
| Q2 2025 | 4% | -1.4 points |
| Q1 2025 | 3.2% | -6.6 points |
| Q4 2024 | 6.5% | -3.7 points |
SMCI has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SMCI on cash generation, producing positive trailing cash flow while its opponent burns cash.
SMCI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$475.6M | +$474.2M |
| Q2 2026 | $718.7M | -15% |
| Q1 2026 | -$6.7B | -1227% |
| Q4 2025 | -$45.1M | +$222.2M |
| Q3 2025 | -$949.8M | -360% |
| Q2 2025 | $840.9M | +$1.5B |
| Q1 2025 | $594.1M | +$2.2B |
| Q4 2024 | -$267.3M | +$342.5M |
SMCI's free cash flow was −$6.5B over the past year, against $218M the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SMCI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | 0.2x | Very low |
SMCI has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SMCI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 19.1 | Oversold |
SMCI's weekly RSI is 41 (neutral) and its Stochastic is 19 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SMCI PE vs Technology Sector
| Metric | SMCI | Sector median | Relative |
|---|---|---|---|
| PE | 5.7x | 28x | 80% below |
| PE % | 0 | 35 | 35 pts below |
SMCI is trading at 5.7x earnings, a 80% discount to the Technology sector's median of 28x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SMCI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.3 | 23% below |
| 20 week MA | $34.2 | 21% below |
| 50 week MA | $32.3 | 17% below |
| 100 week MA | $36.9 | 27% below |
| 200 week MA | $39.8 | 32% below |
SMCI is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SMCI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.41 | $3.05 | +27% |
| 2021 | $3.05 | $4.27 | +40% |
| 2022 | $4.27 | $8.22 | +93% |
| 2023 | $8.22 | $28.4 | +246% |
| 2024 | $28.4 | $32.0 | +12% |
| 2025 | $32.0 | $30.6 | -4.2% |
| 2026 YTD | $30.6 | $27.0 | -12% |
SMCI has the edge over HIMS on returns for 2026, with the stronger performance.